Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77,143,980
-
Total 13F shares
-
40,060,595
-
Share change
-
-22,404
-
Total reported value
-
$561,209,716
-
Price per share
-
$14.01
-
Number of holders
-
108
-
Value change
-
-$19,101,759
-
Number of buys
-
62
-
Number of sells
-
51
Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q1 2022
As of 31 Mar 2022,
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by
108 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,060,595 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, Redmile Group, LLC, BlackRock Inc., BAKER BROS. ADVISORS LP, STATE STREET CORP, VANGUARD GROUP INC, TRV GP III, LLC, EVENTIDE ASSET MANAGEMENT, LLC, WASATCH ADVISORS INC, and PICTET ASSET MANAGEMENT SA.
This page lists
108
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.